JP2025102784A5 - - Google Patents
Info
- Publication number
- JP2025102784A5 JP2025102784A5 JP2025034660A JP2025034660A JP2025102784A5 JP 2025102784 A5 JP2025102784 A5 JP 2025102784A5 JP 2025034660 A JP2025034660 A JP 2025034660A JP 2025034660 A JP2025034660 A JP 2025034660A JP 2025102784 A5 JP2025102784 A5 JP 2025102784A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cas9 polypeptide
- terminal fragment
- cas9
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799702P | 2019-01-31 | 2019-01-31 | |
| US62/799,702 | 2019-01-31 | ||
| PCT/US2020/016285 WO2020160514A1 (en) | 2019-01-31 | 2020-01-31 | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| JP2021544294A JP7646552B2 (ja) | 2019-01-31 | 2020-01-31 | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544294A Division JP7646552B2 (ja) | 2019-01-31 | 2020-01-31 | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025102784A JP2025102784A (ja) | 2025-07-08 |
| JP2025102784A5 true JP2025102784A5 (https=) | 2025-10-31 |
Family
ID=71842366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544294A Active JP7646552B2 (ja) | 2019-01-31 | 2020-01-31 | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| JP2025034660A Pending JP2025102784A (ja) | 2019-01-31 | 2025-03-05 | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544294A Active JP7646552B2 (ja) | 2019-01-31 | 2020-01-31 | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3918078A4 (https=) |
| JP (2) | JP7646552B2 (https=) |
| KR (1) | KR20210121113A (https=) |
| CN (1) | CN114040977B (https=) |
| AU (1) | AU2020215730A1 (https=) |
| CA (1) | CA3127493A1 (https=) |
| WO (1) | WO2020160514A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121555430A (zh) | 2018-05-11 | 2026-02-24 | 比姆医疗股份有限公司 | 使用可编程碱基编辑器系统取代病原性氨基酸的方法 |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| IL296024A (en) | 2020-03-04 | 2022-10-01 | Flagship Pioneering Innovations Vi Llc | Methods and compositions for modulating a genome |
| WO2021222318A1 (en) | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
| CA3194019A1 (en) * | 2020-09-04 | 2022-03-10 | National University Corporation Kobe University | Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| CN116601293A (zh) * | 2020-12-07 | 2023-08-15 | 中国科学院动物研究所 | 工程化的Cas效应蛋白及其使用方法 |
| CN113308451B (zh) * | 2020-12-07 | 2023-07-25 | 中国科学院动物研究所 | 工程化的Cas效应蛋白及其使用方法 |
| CA3214494A1 (en) * | 2021-03-26 | 2022-09-29 | Beam Therapeutics Inc. | Adenosine deaminase variants and uses thereof |
| WO2022221699A1 (en) * | 2021-04-16 | 2022-10-20 | Beam Therapeutics, Inc. | Genetic modification of hepatocytes |
| WO2023283092A1 (en) * | 2021-07-06 | 2023-01-12 | Prime Medicine, Inc. | Compositions and methods for efficient genome editing |
| JP2024533311A (ja) | 2021-09-08 | 2024-09-12 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ゲノムを調節するための方法及び組成物 |
| CN117925585A (zh) * | 2022-04-07 | 2024-04-26 | 尧唐(上海)生物科技有限公司 | 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途 |
| WO2025119307A1 (zh) * | 2023-12-06 | 2025-06-12 | 北京齐禾生科生物科技有限公司 | 优化的qbe碱基编辑系统及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150165054A1 (en) * | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| CA2971444A1 (en) * | 2014-12-20 | 2016-06-23 | Arc Bio, Llc | Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins |
| TWI813532B (zh) * | 2015-06-18 | 2023-09-01 | 美商博得學院股份有限公司 | 降低脱靶效應的ｃｒｉｓｐｒ酶突變 |
| WO2017048969A1 (en) * | 2015-09-17 | 2017-03-23 | The Regents Of The University Of California | Variant cas9 polypeptides comprising internal insertions |
| JP7109784B2 (ja) * | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| WO2018119359A1 (en) * | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CA3057192A1 (en) * | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| EP3625342B1 (en) * | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| AU2018290843B2 (en) * | 2017-06-26 | 2025-04-24 | Massachusetts Institute Of Technology | CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
-
2020
- 2020-01-31 KR KR1020217026724A patent/KR20210121113A/ko active Pending
- 2020-01-31 JP JP2021544294A patent/JP7646552B2/ja active Active
- 2020-01-31 WO PCT/US2020/016285 patent/WO2020160514A1/en not_active Ceased
- 2020-01-31 CA CA3127493A patent/CA3127493A1/en active Pending
- 2020-01-31 EP EP20748889.1A patent/EP3918078A4/en active Pending
- 2020-01-31 AU AU2020215730A patent/AU2020215730A1/en active Pending
- 2020-01-31 CN CN202080026678.0A patent/CN114040977B/zh active Active
-
2025
- 2025-03-05 JP JP2025034660A patent/JP2025102784A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025102784A5 (https=) | ||
| US20220213507A1 (en) | Aav delivery of nucleobase editors | |
| US20250115884A1 (en) | TAL-Tet1 Fusion Proteins and Methods of Use Thereof | |
| US12157760B2 (en) | Base editors and uses thereof | |
| US11840694B2 (en) | Truncated CRISPR-Cas proteins for DNA targeting | |
| AU2018272067B2 (en) | Base editors with improved precision and specificity | |
| JPWO2020160514A5 (https=) | ||
| EP3178935B1 (en) | Genome editing using campylobacter jejuni crispr/cas system-derived rgen | |
| CN110520163A (zh) | 独立于dna双链断裂的靶向基因编辑平台及其用途 | |
| EP3676287A1 (en) | Fusion proteins for improved precision in base editing | |
| CN110612353A (zh) | 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向 | |
| JP2017018125A5 (https=) | ||
| JP2016537008A5 (https=) | ||
| EP2776560A2 (en) | Endonuclease for genome editing | |
| JPWO2020168132A5 (https=) | ||
| JPWO2021050571A5 (https=) | ||
| Li et al. | Site-directed RNA editing by harnessing ADARs: advances and challenges | |
| CN118147120A (zh) | 胞苷脱氨酶及碱基编辑器 | |
| JP2021522825A5 (https=) | ||
| JPWO2020181102A5 (https=) | ||
| JPWO2020219908A5 (https=) | ||
| JPWO2022204574A5 (https=) | ||
| US20200263204A1 (en) | Composition for treating hemophilia a by crispr/cas system of reverting fviii gene inversion | |
| KR20250148471A (ko) | 핵산 결합 단백질 및 SsdA를 포함하는 융합단백질 및 이의 용도 | |
| JP7823919B2 (ja) | エピゲノムが改変された動植物の親系統の製造に用いるための組成物およびその用途 |